YII OIPE

Typed or printed

Signature

Total Number of Pages in This Submission

ě

PTO/SB/21 (03-Approved for use through 04/30/2003, OMB 0651-00

Date


Under the Palerwork Reduction Act of 1995.	, no perso	U.S. Pate	ent and Trademark Office: II	S. DEPARTMENT OF COMMERCE lisplays a valid OMB control number.
TRANSMITTAL FORM to be used for all correspondence after initial filing)		Application Number	09/761,640	RECEIVED
		Filing Date	January 18, 2001	HEULIVED
		First Named Inventor	Ming-Hui WEI	MAD A 8 2004
		Art Unit	1636	MAR 0 8 2004
		Examiner Name	Q. Nguyen	
ntal Number of Degag in This Submission		Attorney Docket Number	CL000964CIP	

	ENCLOSURES (Check all that apply)						
	Fee Transmittal Form	Drawing(s) After Allowance Communication to a Technology Center (TC) Appeal Communication to Board					
	Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/	Licensing-related Papers Petition Petition to Convert to a Provisional Application Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Petition Of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):					
	Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Lin Sun-Hoffman, Registration No. 47,983 or Individual							
Signature							
Date	Date February 27, 2004						
CERTIFICATE OF TRANSMISSION/MAILING							
I hereby	I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



In re Application of: WEI et al.

Art Unit: 1636

Serial No.: 09/761,640

Examiner: Q. Nguyen

Filed: January 18, 2001

Atty. Docket: CL000964 CIP

For: ISOLATED HUMAN PHOSPHATASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN PHOSPHATASE PROTEINS, AND USES THEREOF

RECEIVED

MAR 0 8 2004

Response to 1st Office Action

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action issued by Examiner Nguyen on August 27, 2003, Applicants request reconsideration of the above-referenced patent application in view of the following amendments and remarks. Please charge the attached Petition for Three-Month Extension of Time to Deposit Account No. 50-0970.

In the claim:

- 1-3 (Canceled).
- 4. (Currently Amended) An isolated nucleic acid molecule encoding a phosphatase protein consisting of a nucleotide sequence selected from the group consisting of:
- (a) a nucleotide sequence that encodes a protein comprising the an amino acid sequence of SEQ ID NO:2;
 - (b) a nucleotide sequence consisting of the nucleic acid sequence of SEQ ID

NO:1; and

NO:3.

- (c) a nucleotide sequence consisting of the nucleic acid sequence of SEQ ID
- 5-7 (Canceled).
- 8. (Previously presented) A nucleic acid vector comprising a nucleic acid molecule of claim 4.